ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraakEnglish 
    • EnglishEnglish
    • norsknorsk
  • Administration/UB
View Item 
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
  •   Home
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

C-X-C ligand 16 is an independent predictor of cardiovascular death and morbidity in acute coronary syndromes

Permanent link
https://hdl.handle.net/10037/17539
DOI
https://doi.org/10.1161/ATVBAHA.119.312633
Thumbnail
View/Open
article.pdf (1003.Kb)
Accepted manuscript version Article+ fig. 1, 2 & 3 + supplement (PDF)
Date
2019-09-26
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Author
Andersen, Thomas; Ueland, Thor; Ghukasyan Lakic, Tatevik; Åkerblom, Axel; Bertilsson, Maria; Aukrust, Pål; Michelsen, Annika E; James, Stefan K.; Becker, Richard C.; Storey, Robert F.; Wallentin, Lars; Siegbahn, Agneta; Kontny, Frederic
Abstract
Objective: - The chemokine CXCL16 (C-X-C motif ligand 16) is a scavenger receptor for OxLDL (oxidized low-density lipoproteins) and involved in inflammation at sites of atherosclerosis. This study aimed to investigate the association of CXCL16 with clinical outcome in patients with acute coronary syndrome.

Approach and Results: - Serial measurements of CXCL16 were performed in a subgroup of 5142 patients randomized in the PLATO trial (Platelet Inhibition and Patient Outcome). Associations between CXCL16 and a composite of cardiovascular death, spontaneous myocardial infarction or stroke, and the individual components were assessed by multivariable Cox regression analyses. The hazard ratio per 50% increase in admission levels of CXCL16 analyzed as continuous variable was 1.64 (95% CI, 1.44–1.88), P<0.0001. This association remained statistically significant after adjustment for randomized treatment, clinical variables, CRP (C-reactive protein), leukocytes, cystatin C, NT-proBNP (N-terminal pro-brain natriuretic peptide), troponin T, GDF-15 (growth differentiation factor 15), and other biomarkers; hazard ratio 1.23 (1.05–1.45), P=0.0126. The admission level of CXCL16 was independently associated with cardiovascular death (1.50 [1.17–1.92], P=0.0014) but not with ischemic events alone, in fully adjusted analyses. No statistically independent association was found between CXCL16 measured at 1 month, or change in CXCL16 from admission to 1 month, and clinical outcomes.

Conclusions: - In patients with acute coronary syndrome, admission level of CXCL16 is independently related to adverse clinical outcomes, mainly driven by an association to cardiovascular death. Thus, CXCL16 measurement may enhance risk stratification in patients with this condition.

Publisher
American Heart Association
Citation
Andersen T, Ueland T, Ghukasyan Lakic, Åkerblom A, Bertilsson M, Aukrust P, Michelsen A, James SK, Becker RC, Storey RF, Wallentin L, Siegbahn A, Kontny F. C-X-C ligand 16 is an independent predictor of cardiovascular death and morbidity in acute coronary syndromes. Arteriosclerosis, Thrombosis and Vascular Biology. 2019;39(11):2402-2410
Metadata
Show full item record
Collections
  • Artikler, rapporter og annet (klinisk medisin) [1974]
© 2019 American Heart Association, Inc.

Browse

Browse all of MuninCommunities & CollectionsAuthor listTitlesBy Issue DateBrowse this CollectionAuthor listTitlesBy Issue Date
Login

Statistics

View Usage Statistics
UiT

Munin is powered by DSpace

UiT The Arctic University of Norway
The University Library
uit.no/ub - munin@ub.uit.no

Accessibility statement (Norwegian only)